Literature DB >> 28133631

Gastrointestinal Manifestations of Systemic Sclerosis.

Andrew B Shreiner1, Charles Murray2, Christopher Denton2, Dinesh Khanna3.   

Abstract

In patients with systemic sclerosis (SSc), gastrointestinal (GI) tract involvement is almost universal. Any segment of the GI tract from mouth to anus can be involved, and GI symptoms are a frequent cause of morbidity. In severe cases, GI tract involvement can progress to the point of malnutrition requiring parenteral nutrition. GI tract involvement in SSc contributes to disease-related mortality although mostly as a co-morbidity rather than direct cause of death. The review is intended to help address challenges in the assessment and treatment of GI tract involvement in SSc.

Entities:  

Keywords:  gastrointestinal; motility; scleroderma; systemic sclerosis

Year:  2016        PMID: 28133631      PMCID: PMC5267349          DOI: 10.5301/jsrd.5000214

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  86 in total

Review 1.  What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?

Authors:  Yolanda Braun-Moscovici; Marius Braun; Dinesh Khanna; Alexandra Balbir-Gurman; Daniel E Furst
Journal:  Clin Exp Rheumatol       Date:  2015-08-31       Impact factor: 4.473

2.  Small intestinal manometry in patients with systemic sclerosis.

Authors:  Kristina Sjölund; Izabella Bartosik; Greger Lindberg; Agneta Scheja; Marie Wildt; Anita Akesson
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-11       Impact factor: 2.566

3.  Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.

Authors:  Chingching Foocharoen; Kitti Chunlertrith; Pisaln Mairiang; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Suwassa Namvijit; Orathai Wantha; Ratanavadee Nanagara
Journal:  Rheumatology (Oxford)       Date:  2016-05-13       Impact factor: 7.580

4.  Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications.

Authors:  B W Jaffin; P Chang; H Spiera
Journal:  J Clin Gastroenterol       Date:  1997-10       Impact factor: 3.062

5.  Esophageal involvement and pulmonary manifestations in systemic sclerosis.

Authors:  I Marie; S Dominique; H Levesque; P Ducrotté; P Denis; M F Hellot; H Courtois
Journal:  Arthritis Rheum       Date:  2001-08

6.  Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.

Authors:  Tracy M Frech; Dinesh Khanna; Paul Maranian; Edward J Frech; Allen D Sawitzke; Maureen A Murtaugh
Journal:  Clin Exp Rheumatol       Date:  2011-05-12       Impact factor: 4.473

7.  Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study.

Authors:  Etienne Ghrénassia; Jérome Avouac; Dinesh Khanna; Chris T Derk; Oliver Distler; Yossra Atef Suliman; Paolo Airo; Patricia E Carreira; Rosario Foti; Brigitte Granel; Alice Berezne; Jean Cabane; Francesca Ingegnoli; Edoardo Rosato; Paola Caramaschi; Roger Hesselstrand; Ulrich A Walker; Juan Jose Alegre-Sancho; Virginie Zarrouk; Christian Agard; Valeria Riccieri; Elena Schiopu; Heather Gladue; Virginia D Steen; Yannick Allanore
Journal:  J Rheumatol       Date:  2013-12-01       Impact factor: 4.666

Review 8.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

9.  Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence.

Authors:  Gregory J Heyt; Mina K Oh; Nazanin Alemzadeh; Susie Rivera; Sergio A Jimenez; Satish Rattan; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

10.  Effects of cisapride on colonic transit in patients with progressive systemic sclerosis.

Authors:  S-J Wang; J-L Lan; J-L Lan; D-Y Chen; Y-H Chen; T-Y Hsieh; W-Y Lin
Journal:  Clin Rheumatol       Date:  2002-08       Impact factor: 2.980

View more
  39 in total

1.  Systemic Sclerosis and Pulmonary Disease.

Authors:  Khoa Ngo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Evaluation of risk factors for pseudo-obstruction in systemic sclerosis.

Authors:  Eric Dein; Pei-Lun Kuo; Yun Soo Hong; Laura K Hummers; Christopher A Mecoli; Zsuzsanna H McMahan
Journal:  Semin Arthritis Rheum       Date:  2019-05-23       Impact factor: 5.532

Review 3.  Intestinal Involvement in Systemic Sclerosis: A Clinical Review.

Authors:  Lazaros I Sakkas; Theodora Simopoulou; Dimitrios Daoussis; Stamatis-Nick Liossis; Spyros Potamianos
Journal:  Dig Dis Sci       Date:  2018-02-21       Impact factor: 3.199

4.  Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.

Authors:  Yossra Suliman; Suzanne Kafaja; Sunny J Oh; Mohamed Alemam; Gianluca Bagnato; Giuseppina Abignano; Ram Raj Singh; Gillian Barlow; Xiaochen Liu; Isela Valera; Walter Morales; Ali Rezaie; Mark Pimentel; Francesco Del Galdo; Daniel E Furst
Journal:  Clin Rheumatol       Date:  2020-11-24       Impact factor: 2.980

5.  MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Authors:  Xiangguang Shi; Qingmei Liu; Na Li; Wenzhen Tu; Ruoyu Luo; Xueqian Mei; Yanyun Ma; Weihong Xu; Haiyan Chu; Shuai Jiang; Zhimin Du; Han Zhao; Liang Zhao; Li Jin; Wenyu Wu; Jiucun Wang
Journal:  Cell Cycle       Date:  2018-09-17       Impact factor: 4.534

Review 6.  [Current treatment of systemic scleroderma].

Authors:  Nicolas Hunzelmann
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

7.  Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis.

Authors:  Gianluca Moroncini; Devis Benfaremo; Alessandra Mandolesi; Armando Gabrielli
Journal:  BMJ Case Rep       Date:  2018-05-18

8.  Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis.

Authors:  Dinesh Khanna; Jennifer Serrano; Veronica J Berrocal; Richard M Silver; Pedro Cuencas; Sharon L Newbill; Josephine Battyany; Cynthia Maxwell; Mary Alore; Laura Dyas; Robert Riggs; Kerri Connolly; Saville Kellner; Jody J Fisher; Erica Bush; Anjali Sachdeva; Luke Evnin; Dennis W Raisch; Janet L Poole
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-02-05       Impact factor: 4.794

9.  Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.

Authors:  Zsuzsanna H McMahan; Ana E Tucker; Jamie Perin; Elizabeth R Volkmann; Subhash Kulkarni; Harvey A Ziessman; Pankaj J Pasricha; Fredrick M Wigley
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01-25       Impact factor: 4.794

10.  Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial.

Authors:  Anna-Maria Hoffmann-Vold; Håvard H Fretheim; Vikas K Sarna; Imon Barua; Maylen N Carstens; Oliver Distler; Dinesh Khanna; Elizabeth R Volkmann; Øyvind Midtvedt; Henriette Didriksen; Alvilde Dhainaut; Anne-Kristine Halse; Gunnstein Bakland; Maiju Pesonen; Inge Olsen; Øyvind Molberg
Journal:  BMJ Open       Date:  2021-06-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.